Madhu Kumar
Stock Analyst at Goldman Sachs
(2.83)
# 1,498
Out of 5,182 analysts
142
Total ratings
55.1%
Success rate
19.57%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Madhu Kumar
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| JAZZ Jazz Pharmaceuticals | Maintains: Buy | $162 → $185 | $203.98 | -9.30% | 8 | Aug 29, 2025 | |
| FULC Fulcrum Therapeutics | Maintains: Neutral | $5 → $6 | $7.44 | -19.35% | 8 | Jan 26, 2024 | |
| UTZ Utz Brands | Maintains: Neutral | $19 → $17 | $8.01 | +112.23% | 2 | Nov 10, 2023 | |
| ALEC Alector | Initiates: Sell | $4 | $2.39 | +67.36% | 4 | Sep 25, 2023 | |
| KRYS Krystal Biotech | Maintains: Buy | $135 → $155 | $269.27 | -42.44% | 13 | May 22, 2023 | |
| CYTK Cytokinetics | Maintains: Buy | $48 → $53 | $60.69 | -12.67% | 4 | May 5, 2023 | |
| DSGN Design Therapeutics | Upgrades: Neutral | n/a | $12.81 | - | 3 | May 4, 2023 | |
| ARWR Arrowhead Pharmaceuticals | Maintains: Buy | $65 → $73 | $70.13 | +4.09% | 10 | May 3, 2023 | |
| APLS Apellis Pharmaceuticals | Maintains: Buy | $124 → $141 | $40.99 | +243.99% | 9 | Apr 14, 2023 | |
| SNDX Syndax Pharmaceuticals | Maintains: Buy | $39 → $34 | $21.11 | +61.06% | 6 | Mar 1, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $20 → $6 | $3.38 | +77.51% | 8 | Dec 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sell | $8 → $14 | $8.87 | +57.84% | 6 | Nov 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sell | $5 | $30.99 | -83.87% | 3 | Aug 25, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sell | $10 → $8 | $3.06 | +161.44% | 4 | May 24, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $111 → $89 | $10.22 | +770.84% | 4 | May 24, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $580 → $120 | $5.78 | +1,976.12% | 1 | Jan 19, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $60 → $85 | $13.20 | +543.94% | 7 | Jun 23, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $23 → $39 | $4.00 | +875.00% | 3 | Mar 16, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $58 → $57 | $18.05 | +215.79% | 3 | Jul 31, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $4.15 | - | 15 | Jul 24, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $900 | $0.84 | +107,439.73% | 1 | Apr 21, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underperform | $17 → $20 | $10.28 | +94.55% | 2 | Mar 27, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $5,600 → $4,000 | $5.72 | +69,830.07% | 5 | Mar 13, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $35 | $46.73 | -25.10% | 1 | Mar 12, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $58 → $40 | $13.47 | +196.96% | 2 | Sep 24, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $504 | $27.06 | +1,762.53% | 3 | Oct 8, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $210 → $230 | $302.11 | -23.87% | 2 | Aug 13, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $150 → $1,125 | $23.96 | +4,595.33% | 2 | Feb 9, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $40 | $1.67 | +2,295.21% | 1 | Feb 8, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Buy | $22 | $34.58 | -37.83% | 1 | Dec 1, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $24 | $52.06 | -54.86% | 1 | Mar 28, 2017 |
Jazz Pharmaceuticals
Aug 29, 2025
Maintains: Buy
Price Target: $162 → $185
Current: $203.98
Upside: -9.30%
Fulcrum Therapeutics
Jan 26, 2024
Maintains: Neutral
Price Target: $5 → $6
Current: $7.44
Upside: -19.35%
Utz Brands
Nov 10, 2023
Maintains: Neutral
Price Target: $19 → $17
Current: $8.01
Upside: +112.23%
Alector
Sep 25, 2023
Initiates: Sell
Price Target: $4
Current: $2.39
Upside: +67.36%
Krystal Biotech
May 22, 2023
Maintains: Buy
Price Target: $135 → $155
Current: $269.27
Upside: -42.44%
Cytokinetics
May 5, 2023
Maintains: Buy
Price Target: $48 → $53
Current: $60.69
Upside: -12.67%
Design Therapeutics
May 4, 2023
Upgrades: Neutral
Price Target: n/a
Current: $12.81
Upside: -
Arrowhead Pharmaceuticals
May 3, 2023
Maintains: Buy
Price Target: $65 → $73
Current: $70.13
Upside: +4.09%
Apellis Pharmaceuticals
Apr 14, 2023
Maintains: Buy
Price Target: $124 → $141
Current: $40.99
Upside: +243.99%
Syndax Pharmaceuticals
Mar 1, 2023
Maintains: Buy
Price Target: $39 → $34
Current: $21.11
Upside: +61.06%
Dec 9, 2022
Downgrades: Neutral
Price Target: $20 → $6
Current: $3.38
Upside: +77.51%
Nov 10, 2022
Maintains: Sell
Price Target: $8 → $14
Current: $8.87
Upside: +57.84%
Aug 25, 2022
Downgrades: Sell
Price Target: $5
Current: $30.99
Upside: -83.87%
May 24, 2022
Maintains: Sell
Price Target: $10 → $8
Current: $3.06
Upside: +161.44%
May 24, 2022
Maintains: Buy
Price Target: $111 → $89
Current: $10.22
Upside: +770.84%
Jan 19, 2022
Downgrades: Neutral
Price Target: $580 → $120
Current: $5.78
Upside: +1,976.12%
Jun 23, 2021
Maintains: Neutral
Price Target: $60 → $85
Current: $13.20
Upside: +543.94%
Mar 16, 2021
Upgrades: Outperform
Price Target: $23 → $39
Current: $4.00
Upside: +875.00%
Jul 31, 2020
Upgrades: Outperform
Price Target: $58 → $57
Current: $18.05
Upside: +215.79%
Jul 24, 2020
Downgrades: Neutral
Price Target: n/a
Current: $4.15
Upside: -
Apr 21, 2020
Initiates: Outperform
Price Target: $900
Current: $0.84
Upside: +107,439.73%
Mar 27, 2020
Maintains: Underperform
Price Target: $17 → $20
Current: $10.28
Upside: +94.55%
Mar 13, 2020
Maintains: Buy
Price Target: $5,600 → $4,000
Current: $5.72
Upside: +69,830.07%
Mar 12, 2020
Initiates: Outperform
Price Target: $35
Current: $46.73
Upside: -25.10%
Sep 24, 2019
Maintains: Buy
Price Target: $58 → $40
Current: $13.47
Upside: +196.96%
Oct 8, 2018
Upgrades: Buy
Price Target: $504
Current: $27.06
Upside: +1,762.53%
Aug 13, 2018
Maintains: Buy
Price Target: $210 → $230
Current: $302.11
Upside: -23.87%
Feb 9, 2018
Maintains: Buy
Price Target: $150 → $1,125
Current: $23.96
Upside: +4,595.33%
Feb 8, 2018
Initiates: Buy
Price Target: $40
Current: $1.67
Upside: +2,295.21%
Dec 1, 2017
Reinstates: Buy
Price Target: $22
Current: $34.58
Upside: -37.83%
Mar 28, 2017
Initiates: Buy
Price Target: $24
Current: $52.06
Upside: -54.86%